Brentuximab Vedotin Combined with ABVD or AVD for Newly Diagnosed Advanced-Stage Hodgkin Lymphoma


Brentuximab Vedotin Combined with ABVD or AVD for Newly Diagnosed Advanced-Stage Hodgkin Lymphoma
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/6/15)
Connors JM et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: Long term outcomes. Proc ASH 2014;Abstract 292.

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology, Attending Physician for Lymphoma and Adult BMT Services, Member of Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Medical College of Cornell University in New York, New York.